FDA approves DiaSorin tests and DiaSorin stock costs EUR 77.46

Published on 10/16/2026 at 10:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue was EUR 602 million, flat. DiaSorin stock costs EUR 77.46 on October 16, 2026, 2.84 percent below its 52-week high of EUR 79.72.

Approval and operating milestones

DiaSorin obtained FDA approval for its first automated Parvovirus B19 serology tests on October 13, 2026.
First-half 2026 revenue reached EUR 602.0 million, while second-quarter growth was 4.00 percent at constant exchange rates.
DiaSorin stock traded at EUR 77.46 at 9:48 a.m. CEST at Lang & Schwarz on October 16, 2026.
Third-quarter 2026 results are scheduled for November 12, 2026.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin (IT0003492391) traded at EUR 77.46 at Lang & Schwarz on October 16, 2026, at 9:48 a.m. CEST. On October 13, the diagnostics company obtained FDA approval for its first automated Human Parvovirus B19 IgM and IgG tests on the LIAISON XL system, according to DiaSorin.

FDA approval adds one test milestone

The approval gives DiaSorin a concrete regulatory milestone in its immunodiagnostics business. The company describes the products as its first automated tests for Parvovirus B19 serology on LIAISON XL, connecting the announcement to an established platform rather than a new operating segment.

Three dated steps shape the story

On July 31, 2026, DiaSorin presented first-half results showing EUR 602 million of revenue and adjusted EBITDA of EUR 194 million, according to the Yahoo Finance transcript. On October 7, 2026, the company completed a EUR 250 million share buyback after purchasing 3,790,952 shares, as Repubblica reported. On October 13, 2026, DiaSorin disclosed the FDA approval for the Parvovirus B19 tests through its investor-relations page.

What does the next quarter need to show?

The second-quarter 2026 figures showed revenue growth of 4.00 percent at constant exchange rates, compared with flat growth in the first quarter, while adjusted EBITDA reached EUR 199.394 million for the first half and the adjusted EBITDA margin stood at 32.00 percent. Management confirmed full-year 2026 guidance for revenue growth of 5.00 percent to 6.00 percent and an adjusted EBITDA margin of 32.00 percent to 33.00 percent in the earnings-call transcript. The main operating test is whether the United States recovery and new molecular products can offset continued pressure in China.

Next reporting date is November 12

The next substantiated company date is November 12, 2026, when DiaSorin is scheduled to communicate its third-quarter 2026 results, according to FTA Online. The results will provide the next dated test of the guidance and the commercial contribution from the companys newer diagnostic platforms.

Stock price and reporting date

DiaSorin stock was trading at EUR 77.46 at Lang & Schwarz on October 16, 2026, at 9:48 a.m. CEST. The quote stood 2.84 percent below the 52-week high of EUR 79.72 from the same market snapshot. The next reporting date is November 12, 2026.

The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.